ライフサイエンスコーパス: ventilator

1 ventilation in conjunction with a mechanical ventilator.

2 contributes to problems in weaning from the ventilator.

3 from life support devices such as mechanical ventilators.

4 (22%), 21 adult (21%) and 5 pediatric (19%) ventilators, 14 anesthesia machines (10%), and 116 oxyge

5 as sepsis (42%), followed by failure to wean ventilator (31%), and organ space surgical site infectio

6 r clinical findings (e.g., triggering of the ventilator and degree of shivering) to assess the degree

7 Patients on VA-ECMO were more often on ventilator and dialysis and had a higher bilirubin level

8 sion was strongly associated with death on a ventilator and type II pneumocyte hyperplasia.

9 ay, total length of stay, days on mechanical ventilator, and Marshall Multiple Organ Dysfunction scor

10 , new or progressive multiorgan dysfunction, ventilator- and vasoactive-free days at Day 28, function

11 pe II pneumocytes, cells that proliferate in ventilator associated lung injury.

12 ients with respiratory tract colonization or ventilator- associated pneumonia.

13 The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is

14 e of the leading causes of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP).

15 apies for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).

16 a-D-glucan level evolution, and incidence of ventilator-associated bacterial pneumonia.

17 of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

18 ring the same time period, infection-related ventilator-associated complication and possible and prob

19 r-associated condition and infection-related ventilator-associated complication episodes, and ventila

20 nts met the criteria for either an infective ventilator-associated complication or pneumonia (placebo

21 ificant gastrointestinal bleeding, infective ventilator-associated complication or pneumonia, and Clo

22 ntilator-associated event, infection-related ventilator-associated complication, and probable ventila

23 We applied the definition for ventilator-associated condition (i.e., a sustained incre

24 A good correlation was observed between ventilator-associated condition and infection-related ve

25 sed hospital mortality compared with the non-ventilator-associated condition group (19.3% vs 6.9%; p=

26 The ventilator-associated condition group had increased hosp

27 Patients who developed ventilator-associated condition had significantly longer

28 Risk factors for developing a ventilator-associated condition included immunocompromis

29 Ventilator-associated condition prevalence was 21.8% in

30 30/mean airway pressure 7 definition yielded ventilator-associated condition rates of 1.1-1.3 per 1,0

31 We matched patients with a ventilator-associated condition to those without and use

32 nor mortality differed between groups; only ventilator-associated condition was associated with incr

33 sociated pneumonia, 25 (58.2%) experienced a ventilator-associated condition.

34 ence and to assess its concomitant impact on ventilator-associated conditions and antibiotic use.

35 Pediatric patients with ventilator-associated conditions are at substantially hi

36 The definitions for the various ventilator-associated conditions are good predictors of

37 pressure 4 thresholds to identify pediatric ventilator-associated conditions in ICUs.

38 New definitions of ventilator-associated conditions involving worsening oxy

39 ies, and preventative measures for pediatric ventilator-associated conditions.

40 significantly higher in patients without any ventilator-associated event (p < 0.05).

41 ssociated event, 2) the relationship between ventilator-associated event and ventilator-associated pn

42 liance observations and 1,022 unit-months of ventilator-associated event data.

43 Critical care unit pooled mean ventilator-associated event incidence rates ranged from

44 We calculated ventilator-associated event incidence rates, rate distri

45 We found substantial variability in ventilator-associated event incidence, proportions of ve

46 Ventilator-associated event is very common in a populati

47 r-associated pneumonia, and 3) the impact of ventilator-associated event on antimicrobials consumptio

48 The quarterly mean ventilator-associated event rate significantly decreased

49 We describe the collaborative's impact on ventilator-associated event rates in 56 ICUs.

50 acilities reported 32,772 location months of ventilator-associated event surveillance data to the Nat

51 ccurred in 2014, the first year during which ventilator-associated event surveillance definitions wer

52 Ventilator-associated event surveillance was introduced

53 We assess 1) the current epidemiology of ventilator-associated event, 2) the relationship between

54 vidence-based interventions and decreases in ventilator-associated event, infection-related ventilato

55 e, -0.57 d; 95% CI, -2.44 to 1.30; I2 = 0%), ventilator-associated events (risk ratio, 0.97; 95% CI,

56 ed to understand the preventable fraction of ventilator-associated events and identify patient care s

57 Ventilator-associated events are associated with increas

58 r-associated event incidence, proportions of ventilator-associated events characterized as infection-

59 The pooled mean proportion of ventilator-associated events defined as infection-relate

60 mined incidence rates and characteristics of ventilator-associated events reported to the National He

61 reported from U.S. healthcare facilities for ventilator-associated events that occurred in 2014, the

62 entilation, ICU and hospital length of stay, ventilator-associated events, mortality, antibiotic util

63 n of mechanical ventilation, length of stay, ventilator-associated events, mortality, or antibiotic u

64 y funded a two-state collaborative to reduce ventilator-associated events.

65 identify patient care strategies that reduce ventilator-associated events.

66 ent location characteristics associated with ventilator-associated events.

67 te affirming that best practices can prevent ventilator-associated events.

68 patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumo

69 sk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including special

70 lator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).

71 role of improved diagnosis and prevention of ventilator-associated pneumonia also showed relevant res

72 ed with improved outcome in the treatment of ventilator-associated pneumonia although the level of ev

73 ing; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain

74 Use of aerosolised antibiotics for ventilator-associated pneumonia and ventilator-associate

75 ke surveillance of events possibly linked to ventilator-associated pneumonia as objective as possible

76 ver the study period, 20 patients (3.4%) had ventilator-associated pneumonia caused by extended-spect

77 Ventilator-associated pneumonia developed in 20.4% of pa

78 secretion drainage is associated with fewer ventilator-associated pneumonia diagnoses, but it is unc

79 zed invasive techniques for the diagnosis of ventilator-associated pneumonia had lower rates of prolo

80 inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns rec

81 tive cohort study of patients with suspected ventilator-associated pneumonia in a medical ICU was con

82 Network in 2013, replacing surveillance for ventilator-associated pneumonia in adult inpatient locat

83 volvement of such pathogens in patients with ventilator-associated pneumonia in low-prevalence area.

84 Ventilator-associated pneumonia is frequent in ICUs.

85 Ventilator-associated pneumonia is the most important in

86 ing ventilation, microbiologically confirmed ventilator-associated pneumonia occurred in 15 patients

87 ilator-associated complication episodes, and ventilator-associated pneumonia occurrence: R = 0.69 and

88 and in high-risk complex infections such as ventilator-associated pneumonia or sepsis where coloniza

89 effect of subglottic secretion suctioning on ventilator-associated pneumonia prevalence and to assess

90 oning resulted in a significant reduction of ventilator-associated pneumonia prevalence associated wi

91 Existing ventilator-associated pneumonia prevention bundles are u

92 secretion drainage was associated with lower ventilator-associated pneumonia rates (risk ratio, 0.58;

93 secretion drainage is associated with lower ventilator-associated pneumonia rates but does not clear

94 iated complication and possible and probable ventilator-associated pneumonia rates decreased from 3.1

95 In terms of ventilatory days, ventilator-associated pneumonia rates were 9.6 of 1,000

96 ilation, moving from the current standard of ventilator-associated pneumonia to broader complications

97 Each patient with suspected ventilator-associated pneumonia was included in the coho

98 Ventilator-associated pneumonia was the most common type

99 -producing Enterobacteriaceae involvement in ventilator-associated pneumonia were 85.0% and 95.7%, re

100 Effective (aerosolized antibiotics for ventilator-associated pneumonia) and ineffective (procal

101 atients with nosocomial pneumonia (including ventilator-associated pneumonia) caused by Gram-negative

102 Infections (especially ventilator-associated pneumonia) during extracorporeal m

103 Adults with nosocomial pneumonia (including ventilator-associated pneumonia), enrolled at 136 centre

104 Among the 47 patients with ventilator-associated pneumonia, 25 (58.2%) experienced

105 Among 587 patients with suspected ventilator-associated pneumonia, 40 (6.8%) were colonize

106 ted urinary tract infection, 13 versus 8 for ventilator-associated pneumonia, 6 versus 3 for incision

107 ship between ventilator-associated event and ventilator-associated pneumonia, and 3) the impact of ve

108 fied acute physiology score II, diagnosis of ventilator-associated pneumonia, and infection by multid

109 nit (ICU) most commonly manifests as sepsis, ventilator-associated pneumonia, and infection of surgic

110 The pooled incidence density of ventilator-associated pneumonia, central line-associated

111 atients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem

112 We identified 32 ventilator-associated pneumonia, eight urinary tract inf

113 catheter-associated urinary tract infection, ventilator-associated pneumonia, incisional surgical sit

114 ntral line-associated bloodstream infection, ventilator-associated pneumonia, urinary tract infection

115 age as a way to predict their involvement in ventilator-associated pneumonia.

116 ith subglottic secretion drainage to prevent ventilator-associated pneumonia.

117 difficult-to-treat pathogens likely to cause ventilator-associated pneumonia.

118 n the intensive care unit was complicated by ventilator-associated pneumonia.

119 ilator-associated complication, and probable ventilator-associated pneumonia.

120 ubglottic secretions plays a pivotal role in ventilator-associated pneumonia.

121 cus aureus predisposes to the development of ventilator-associated tracheobronchitis (VAT) and ventil

122 tics for ventilator-associated pneumonia and ventilator-associated tracheobronchitis shows promise, b

123 ve tidal volumes and common forms of patient-ventilator asynchrony, and that artifact correction sign

124 reathing events including air leaks, patient-ventilator asynchrony, central sleep apnea, and glottic

125 ed approximately 35,000 to 60,500 additional ventilators, averting a pandemic total 178,000 to 308,00

126 ness following PM exposure in vivo using the ventilator-based flexiVent system.

127 5.4 [10.2] vs 1.8 [5.7] days; P < .001), and ventilator days (1.7 [4.2] vs 0.6 [4.0] days; P < .03).

128 y 4), rates ranged from 2.9 to 3.2 per 1,000 ventilator days depending on ICU type; the fraction of i

129 BSI incidence, organ dysfunction, ventilator days, and time to wound healing (P > 0.05) we

130 Secondary outcomes were ventilator days, ICU days, Short Physical Performance Ba

131 ce rates ranged from 2.00 to 11.79 per 1,000 ventilator days, whereas noncritical care unit rates ran

132 unit rates ranged from 0 to 14.86 per 1,000 ventilator days.

133 mechanically ventilated patients with 75,621 ventilator days.

134 dren with 10,209 hospitalizations and 77,751 ventilator days.

135 ociated condition rates of 1.1-1.3 per 1,000 ventilator days.

136 ed urinary tract infection was 14.7 per 1000 ventilator-days (95% CI, 11.7-17.7), 4.7 per 1000 cathet

137 .15 to 1.56 and 1.41 to 0.31 cases per 1,000 ventilator-days (p = 0.018, p = 0.012), respectively.

138 decreased from 7.34 to 4.58 cases per 1,000 ventilator-days after 24 months of implementation (p = 0

139 nt; 95% confidence interval [CI], .98-1.36), ventilator death (HR, 0.82 [95% CI, .55-1.22]), time to

140 We compared time to extubation alive vs ventilator death and time to hospital discharge alive vs

141 ptic shock (OR = 2.43; 95% CI, 2.20-2.69) or ventilator dependence (OR = 2.81; 95% CI, 2.56-3.09) pre

142 for the management of children with chronic ventilator dependence at home are provided, and the evid

143 Children with chronic invasive ventilator dependence living at home are a diverse group

144 atory muscle, the diaphragm, contributing to ventilator dependence.

145 atrophy and respiratory problems leading to ventilator-dependence.

146 tically ill patients is evident: it prolongs ventilator dependency and increases morbidity, duration

147 erative respiratory failure (RF), defined as ventilator dependency for more than 48 hours or unplanne

148 ffected individuals presented at birth, were ventilator dependent and, where tested, revealed severe

149 matched pairs analysis revealed that time on ventilator (difference of median, 98.5 hr; p = 0.003) an

150 ntractile activity decreased with increasing ventilator driving pressure (P = 0.01) and controlled ve

151 The animals were then placed on a mechanical ventilator, fluid resuscitated, and monitored for 48 hou

152 n and prepare to meet demands for mechanical ventilators for a future severe pandemic.

153 ex change closely approximated mortality and ventilator-free day outcomes in three Acute Respiratory

154 oup, compared with placebo, had fewer median ventilator-free days (1 day [IQR 0 to 17] in the KGF gro

155 s 7.4 [0.1] d; p < 0.0001), had fewer 28-day ventilator-free days (15.7 [0.2] vs 17.5 [0.2] d; p < 0.

156 is trend with 24-hour PaO2/FIO2 was seen for ventilator-free days (22, 19, 14, and 0 ventilator-free

157 1.38; P = .04), decreased the number of mean ventilator-free days (5.3 vs 6.4; difference, -1.1; 95%

158 tal mortality (75% vs 53.4%; p = 0.26), more ventilator-free days (9 [0-21.5] vs 0 [0-12]; p = 0.16),

159 Lower Vt also was associated with more ventilator-free days (beta = 1.78; 95% CI, 0.39-3.16 per

160 Secondary outcomes included 28-day invasive ventilator-free days (ie, days alive without mechanical

161 tio, 0.90; 95% CI, 0.63-1.30; p = 0.585), or ventilator-free days (odds ratio, 1.06; 95% CI, 0.71-1.5

162 1.9 (+/- 12.4) among those with less than 14 ventilator-free days (p = 0.001).

163 fungemia, ICU length of stay, mortality, and ventilator-free days (VFDs) at 28 days.

164 for ventilator-free days (22, 19, 14, and 0 ventilator-free days across worsening Berlin categories;

165 tality (primary outcome), ICU mortality, and ventilator-free days and alive at day 28 were retrospect

166 come measure and compared with mortality and ventilator-free days as reported in the original study.

167 tify variables associated with mortality and ventilator-free days at 28 days in a large cohort of chi

168 (95% CI, 1.3-3.0), as well as an increase in ventilator-free days at day 28 by 3.7 days (95% CI, 3.1-

169 The number of ventilator-free days at day 28 was significantly higher

170 Secondary outcomes included ventilator-free days at day 28, length of stay, and mort

171 gth of ventilation, length of PICU stay, and ventilator-free days at day 28.

172 ICU mortality, ICU-free days, and ventilator-free days did not differ between intervention

173 sed controlled trial assessing mortality and ventilator-free days for rosuvastatin versus placebo for

174 ciated with higher mortality rates and fewer ventilator-free days in comparison to both mild hyperoxi

175 luid-conservative therapy has also increased ventilator-free days in patients with ARDS.

176 After adjustment for potential confounders, ventilator-free days in phase 1 and phase 2 were higher

177 th 1.3 (p = 0.001) and 1.6 (p < 0.001) fewer ventilator-free days than normal weight and overweight,

178 outcomes were 60-day adjusted mortality and ventilator-free days through day 28.

179 tcomes were length of ICU and hospital stay; ventilator-free days through day 28; pneumothorax requir

180 The number of ventilator-free days was significantly higher in the hel

181 ome, conservative fluid management increases ventilator-free days without affecting mortality.

182 ease of 1.71 and for predicting less than 14 ventilator-free days, a decrease of 2.34.

183 ans (interquartile ranges) presented, 28-day ventilator-free days, and hospital mortality were calcul

184 with favorable neurocognitive outcome, more ventilator-free days, and more shock-free days.

185 5.9 (+/- 8.4) in patients with more than 14 ventilator-free days, compared with a decrease of 1.9 (+

186 es including fewer hospital-free days, fewer ventilator-free days, higher hospital charges, and reduc

187 Secondary measures included ventilator-free days, hospital and intensive care unit l

188 re was also no significant difference in the ventilator-free days, ICU, and the hospital length of st

189 ted pneumonia, urinary tract infection, mean ventilator-free days, mean ICU length of stay, mean hosp

190 al replacement therapy-free days, mechanical ventilator-free days, or length of stay in ICU or hospit

191 17-0.83; p = 0.02) and a 3.9 day increase in ventilator-free days, p value equals to 0.01.

192 red infections, length of hospital stay, and ventilator-free days, using multivariate analysis.

193 subsequent trials powered for mortality and ventilator-free days.

194 ren had a higher risk of mortality and fewer ventilator-free days.

195 n oxygenation index for 28-day mortality and ventilator-free days.

196 in oxygenation index, 28-day mortality, and ventilator-free days.

197 ital length of stay, ICU length of stay, and ventilator-free days.

198 erity of organ dysfunction, or the number of ventilator-free days.

199 Dexmedetomidine increased ventilator-free hours at 7 days compared with placebo (m

200 andard care alone (placebo) resulted in more ventilator-free hours at 7 days.

201 Ventilator-free hours in the 7 days following randomizat

202 muscle strength assessments for survival or ventilator-free survival, up to 3 years.

203 l significance for prediction of survival or ventilator-free survival.

204 differences were seen in secondary outcomes: ventilator-free to day 28, mean (SD), 24.9 (7.4) days vs

205 ICUs in Canada generally had more beds, ventilators, healthcare personnel, and rescue oxygenatio

206 controls during direct (bacterial pneumonia, ventilator-induced ALI, bleomycin-induced ALI) and indir

207 RATIONALE: Ventilator-induced diaphragm dysfunction is a significan

208 ng from the ventilator, many of whom acquire ventilator-induced diaphragm dysfunction.

209 ransvenous phrenic nerve pacing may mitigate ventilator-induced diaphragm dysfunction.

210 tive stress are among the major effectors of ventilator-induced diaphragm muscle dysfunction (VIDD),

211 Ventilator-induced diaphragmatic dysfunction (VIDD) refe

212 hich might be one pathophysiologic origin of ventilator-induced diaphragmatic dysfunction.

213 c dysfunction, and a potential mechanism for ventilator-induced fibroproliferation.

214 However, MV causes ventilator-induced lung injury (VILI), a condition chara

215 monitoring of compliance are used to prevent ventilator-induced lung injury (VILI).

216 However, MV can also cause ventilator-induced lung injury (VILI).

217 imize or even abolish the harmful effects of ventilator-induced lung injury if used as an alternative

218 mption of a high-fat diet protects mice from ventilator-induced lung injury in a manner independent o

219 Hydrogen sulfide reduces ventilator-induced lung injury in mice.

220 Fat-fed mice showed clear attenuation of ventilator-induced lung injury in terms of respiratory m

221 riggered mechanism in the protection against ventilator-induced lung injury involves cyclooxygenase 2

222 eir relative contribution to inflammation in ventilator-induced lung injury is not well established.

223 Ventilator-induced lung injury may arise from heterogene

224 of hydrogen sulfide were analyzed in a mouse ventilator-induced lung injury model in vivo as well as

225 y develop lung injury that is similar to the ventilator-induced lung injury observed in mechanically

226 e as a direct and easily measured marker for ventilator-induced lung injury risk.

227 use circulatory depression and contribute to ventilator-induced lung injury through alveolar overdist

228 higher [F]fluorodeoxyglucose uptake rate in ventilator-induced lung injury versus control lung (0.01

229 igned to 4 hours of ventilation of the left (ventilator-induced lung injury) lung with tidal volume o

230 Volutrauma and atelectrauma promote ventilator-induced lung injury, but their relative contr

231 In a classic model of ventilator-induced lung injury, high peak pressure (and

232 ONALE: In the original 1974 in vivo study of ventilator-induced lung injury, Webb and Tierney reporte

233 hanically ventilated patients is the risk of ventilator-induced lung injury, which is partially preve

234 stress and strain are major determinants of ventilator-induced lung injury.

235 and minimize/abolish the harmful effects of ventilator-induced lung injury.

236 me and driving pressure, key determinants of ventilator-induced lung injury.

237 y observed in patients with ARDS by creating ventilator-induced lung injury.

238 ated whether fat feeding protected mice from ventilator-induced lung injury.

239 High strain rate is a risk factor for ventilator-induced pulmonary edema, possibly because it

240 tive inspiratory laryngeal narrowing against ventilator insufflations when inspiratory pressure is in

241 d ventilatory assist provides better patient-ventilator interactions but can be sometimes excessively

242 toward early mobilization, be managed with a ventilator liberation protocol, be assessed with a cuff

243 dations related to rehabilitation protocols, ventilator liberation protocols, and cuff leak tests.

244 ytopenia, preexisting kidney disease, failed ventilator liberation, and acute kidney injury +/- hemod

245 except preexisting kidney disease and failed ventilator liberation, were measured at the time the pat

246 otropic support, attention to rewarming, and ventilator management are key components.

247 Biomarker-directed ventilator management may lead to improved outcomes in w

248 stays in the intensive care unit, prolonged ventilator management, and possible dialysis and tracheo

249 erformed before initiating protocol-directed ventilator management.

250 ventilation have difficulty weaning from the ventilator, many of whom acquire ventilator-induced diap

251 r driving pressure (P = 0.01) and controlled ventilator modes (P = 0.02).

252 -13.2 for the need for controlled mechanical ventilator; OR, 11.0; 95% CI, 2.26-53.8 for the need for

253 breathing reduced via a proportional assist ventilator (PAV).

254 r, the total pressure including muscular and ventilator pressure was calculated.

255 nate breaths at intensities that reduced the ventilator pressure-time product by 20-30%.

256 Significant reductions in ventilator pressure-time-product were achieved during st

257 demonstrates that implementing a mechanical ventilator protocol in the emergency department is feasi

258 An emergency department ventilator protocol which targeted variables in need of

259 pient age, biologic MELD score, recipient on ventilator, recipient hepatitis C virus + serology, dono

260 eumonia, prolonged requirement of mechanical ventilator, sepsis, septic shock, readmission, and reope

261 ted condition (i.e., a sustained increase in ventilator setting after a period of stable or decreasin

262 Lung viscoelastic behavior, with ventilator setting required per protocol, was "quantifie

263 ective ventilation evaluated on standardized ventilator settings 24 hours after acute respiratory dis

264 During ex vivo lung perfusion (EVLP), fixed ventilator settings and monitoring of compliance are use

265 This small, preliminary study shows that ventilator settings currently proposed for EVLP may expo

266 We tested whether currently proposed ventilator settings expose lungs to VILI during EVLP and

267 Patients with minimal and stable ventilator settings may be suitable candidates for early

268 Assessing serial ventilator settings may help clinicians identify candida

269 Use of the stress index to personalize ventilator settings needs to be tested in further clinic

270 he degree of hypoxemia and/or the effects of ventilator settings on gas exchange.

271 Our data suggest that default mechanical ventilator settings should include PEEP of 5-10 cmH2O du

272 ts with suspected VAP but minimal and stable ventilator settings treated with 1-3 days vs >3 days of

273 The median home ventilator settings were an inspiratory positive airway

274 Decreases in DeltaP owing to changes in ventilator settings were strongly associated with increa

275 ts with suspected VAP but minimal and stable ventilator settings.

276 orbidities in patients treated by mechanical ventilator support (invasive or noninvasive) for acute h

277 10.68; P < .001), more than 5 days requiring ventilator support (OR, 9.45; 95% CI, 3.41-26.18; P < .0

278 ents, there is a linear relationship between ventilator support and diaphragmatic atrophy rate.

279 tum women found that more than half required ventilator support, 2 women died, and 6 infants were bor

280 ssessment of critical care impact, including ventilator support, on survival.

281 major cause of failure to wean patients from ventilator support.

282 sive sedation (OR 1.59 [1.09-2.31]) and poor ventilator synchronisation (OR 1.55 [1.05-2.30]).

283 n, agitation, poor limb relaxation, and poor ventilator synchronisation.

284 gitation 4-17%; poor relaxation 13-21%; poor ventilator synchronization 8-17%; and overall optimum se

285 Ventilator synchronization correlated with Behavioral Pa

286 care periods with poor limb relaxation, poor ventilator synchronization, unnecessary deep sedation, a

287 Among the 131 patients on mechanical ventilator, the duration of mechanical ventilation was s

288 ress the percentage of assist assumed by the ventilator, the total pressure including muscular and ve

289 ilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering se

290 Longer duration of ventilator usage and hospitalization was associated with

291 1.3-6.9), was more likely to have prolonged ventilator use (OR, 3.1; 95% CI, 1.2-8.2), and had a lon

292 ent incidence rates, rate distributions, and ventilator utilization ratios in critical care and noncr

293 Pooled mean ventilator utilization ratios in critical care units ran

294 ents characterized as infection-related, and ventilator utilization within and among location types.

295 piratory status during apnea, the mechanical ventilator was paused for up to 2 min during normal brea

296 Ventilator weaning failure and death are more common as

297 e than or equal to 14 days, 2) admitted to a ventilator weaning unit, or 3) received a tracheostomy f

298 ilation prescriptions may be used to set the ventilator with the potential to improve outcomes beyond

299 with 17.3% of the family members agreeing to ventilator withdrawal currently and 67.5% terminally in

300 y predicted that 8 intensive-care beds and 7 ventilators would be sufficient to treat GBS cases.